文献速递乳腺US

超声在评估乳腺癌新辅助化疗反应中的价值

Value of ultrasound in assessing response to neoadjuvant chemotherapy in breast cancer.
PubMed 文献 · Clin Radiol · 2023-07-29

回顾性分析417例乳腺癌患者7年资料,评估超声测量病灶最长径从基线至结束、基线至中期、中期至结束的变化与残余肿瘤负荷分级及病理完全缓解的关系。结果显示最长径变化与残余肿瘤负荷分级呈负相关(有统计学意义),基线至结束和基线至中期的变化与病理完全缓解也呈负相关(P<0.05)。

要点

  • 超声最长径变化越小,残余肿瘤负荷分级越高,呈负相关且有统计学意义。
  • 基线至结束和基线至中期的超声最长径变化与病理完全缓解呈负相关(P<0.05)。
  • 研究支持在化疗开始、中期和结束时使用超声监测新辅助化疗反应。

核心结论

  • 超声测量最长径的缩小程度可作为病理完全缓解和残余肿瘤负荷分级的预测指标,支持在化疗开始、中期和结束时使用超声监测新辅助化疗反应。

研究设计与样本

  • 回顾性研究,纳入417例患者,时间跨度7年;采用logistic回归和有序logistic回归分析超声最长径变化与残余肿瘤负荷分级及病理完全缓解的关系。

诊断标准与关键数值

  • 基线至结束、基线至中期、中期至结束的最长径变化预测残余肿瘤负荷分级均呈负相关,有统计学显著关联。
  • 基线至结束和基线至中期的最长径变化预测病理完全缓解呈负相关,有统计学显著关联(P<0.05)。

临床应用与阅片要点

  • 原文结论认为研究结果支持当前在化疗开始、中期和结束时使用超声监测新辅助化疗反应的做法。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To analyse the utility of ultrasound in assessing response to neoadjuvant chemotherapy (NAC) and predicting residual cancer burden (RCB) index and pathological complete response (pCR) MATERIALS AND METHODS: This was a retrospective study with 417 patients over 7 years. The difference in longest diameter (LD) of the index lesion from baseline to end, baseline to mid, and mid to end was evaluated with respect to RCB class using logistic regression and ordered logistic regression.

RESULTS: Change in LD measurements from baseline to end, baseline to mid, and mid to end of chemotherapy as a predictor of RCB class show a negative relationship with a statistically significant association. This would suggest that a smaller change in LD measurements would be associated with an eventual higher RCB class. Change in LD measurements from baseline to end and baseline to mid chemotherapy as a predictor of pCR class show a negative relationship with a statistically significant association (p<0.05). This similarly indicates an inversely proportional relationship between changes in LD measurements and RCB class 0 for baseline to end and baseline to mid.

CONCLUSION: This study has shown significance in reducing LD measurements on ultrasound as a predictor of PCR and RCB class. This adds weight to the current practice of using ultrasound at the start, mid and end of chemotherapy cycles to monitor NACT responses.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Lim HF, Sharma A, Gallagher C, et al. Value of ultrasound in assessing response to neoadjuvant chemotherapy in breast cancer. Clin Radiol. 2023. PMID: 37734976. doi:10.1016/j.crad.2023.07.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。